Mental health medications: number of users Colombia 2017-2029

The number of patients in the mental health market in Colombia was forecast to continuously increase between 2024 and 2029 by in total 0.6 million users (+15 percent). After the twelfth consecutive increasing year, the number of patients is estimated to reach 4.64 million users and therefore a new peak in 2029. Notably, the number of patients of the mental health market was continuously increasing over the past years.

Find further information concerning the revenue in the mental health market in Chile and the revenue in the mental health market in Spain.

The Statista Market Insights cover a broad range of additional markets.

Number of users of mental health medications in Colombia from 2017 to 2029 (in million users)

Characteristic	Users in millions
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Mental health disorders are common illnesses found among people all over the world. These disorders are caused by a variety of genetic and environmental factors that cause imbalances in a person's physical and emotional behavior. Most mental health disorders can be treated with behavioral and psychotherapies. In some cases, however, medication is prescribed along with these treatments. The Mental Health market represents the market for the drugs that are used to treat various mild to serious mental health disorders. The market is divided into three markets that have been based on the disorders that are being treated. This includes depressive disorders, anxiety and related sleeping disorders, and different types of psychotic disorders.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, Johnson & Johnson, AbbVie, and Sumitomo pharma

Citation formats